|
|
|
08.05.26 - 00:48
|
Live from DoubleLine Capital | The Close 5/7/2026 (Bloomberg)
|
|
|
Bloomberg Television brings you the latest news and analysis leading up to the final minutes and seconds before and after the closing bell on Wall Street. Today's guests are DoubleLine Global Sovereign & Emerging Markets Head Bill Campbell, GTCR Co-CEO Collin Roche, DoubleLine Non-Agency Residential Mortgage-Backed Securities Head Ken Shinoda, Cambridge Associates' Samantha Davidson, DoubleLine Deputy CIO Jeffrey Sherman, DoubleLine Global Developed Credit Director Robert Cohen, Man Group CEO Robyn Grew, & DoubleLine CEO & CIO Jeffrey Gundlach. (Source: Bloomberg)...
|
|
|
07.05.26 - 22:18
|
PE Risk Is Being Priced in a More Rational Way, GTCR′s Roche Says (Bloomberg)
|
|
|
GTCR Co-CEO and Managing Director Collin Roche reflects on the private equity landscape, emphasizing the importance of value creation over merely capitalizing on rising prices. Roche highlights GTCR's multibillion-dollar exit from Worldpay as a prime example of their strategy: backing executive teams to implement operational and strategic changes that improve business performance and justify higher exit multiples. (Source: Bloomberg)...
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
07.05.26 - 07:03
|
Roche enters into a definitive merger agreement to acquire PathAI to transform AI-driven diagnostics (GlobeNewswire EN)
|
|
|
Basel, 7 May 2026 - Roche (SIX: RO, ROP; OTCQX: RHHBY) announced today that it has entered into a definitive merger agreement to acquire PathAI, a US-based company in digital pathology and AI-powered technology for pathology laboratories and the biopharma industry. This acquisition builds on the successful partnership between Roche and PathAI, established in 2021 and scaled up in 2024 to include the development of AI-enabled companion diagnostic algorithms. Subject to the closing of the transaction, which is expected in the second half of the year, the acquired entity will become part of the Diagnostics division....
|
|
|
|
|
|
|
04.05.26 - 12:48
|
Roche Underperform (DPA-AFX)
|
|
|
NEW YORK (dpa-AFX Analyser) - Das Analysehaus Jefferies hat die Einstufung für Roche nach Zahlen auf "Underperform" mit einem Kursziel von 230 Franken belassen. Der Pharmakonzern werde weiterhin mit einem Aufschlag von etwa einem Viertel gegenüber vergleichbaren ......
|
|
|
|
|
|
|
01.05.26 - 16:00
|
Roche Neutral (DPA-AFX)
|
|
|
NEW YORK (dpa-AFX Analyser) - Die US-Bank JPMorgan hat die Einstufung für Roche auf "Neutral" mit einem Kursziel von 325 Franken belassen. Nach den Zahlen des Pharmakonzerns zum ersten Quartal habe er seine Umsatz- und Ergebnisprognosen (Core EPS) für ......
|
|
|
|
|
30.04.26 - 07:03
|
Roche to present extensive data showcasing its industry-leading ophthalmology portfolio at ARVO 2026 (GlobeNewswire EN)
|
|
|
Basel, 30 April 2026 - Roche (SIX: RO, ROP; OTCQX: RHHBY) announced today that it will showcase key real-world, product and pipeline data from its ophthalmology portfolio at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting, held 3rd to 7th of May in Denver, Colorado, USA. The data being presented emphasise Roche's focus on preserving vision through innovative therapies, including Vabysmo® (faricimab), Susvimo® (Port Delivery Platform with ranibizumab) and the investigational interleukin-6 (IL-6) inhibitor, vamikibart. The data cover five retinal conditions including geographic atrophy (GA), retinal vein occlusion (RVO) and uveitic macular edema (UME) as well as diabetic macular edema (DME) and neovascular age-related macular degeneration (nAMD)....
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
